| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
TDP43 IMMUNOHISTOCHEMISTRY (IHC)
MessageThis test is ordered by pathologists.
Test Code
1230300846
CPT Codes
88342-TC, Primary;88341-TC, if additional IHC
Preferred Specimen
Tissue
Methodology
Immunohistochemistry (IHC)
FDA Status
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by WVUH in a manner consistent with CLIA requirements.
Clinical Significance
TDP-43, a heterogeneous nuclear ribonucleoprotein, was identified as a component of ubiquitin-positive and tau-negative inclusions observed
in cases of frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Immunochemical analyses using
antibodies generated against phospho- and non-phosphopeptides of human TDP-43 revealed that abnormally phosphorylated full-length
TDP-43 (45 kDa), C-terminal fragments (~25 kDa) and smearing substances are deposited as intracellular inclusions in affected regions of FTLDU and ALS cases.
in cases of frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Immunochemical analyses using
antibodies generated against phospho- and non-phosphopeptides of human TDP-43 revealed that abnormally phosphorylated full-length
TDP-43 (45 kDa), C-terminal fragments (~25 kDa) and smearing substances are deposited as intracellular inclusions in affected regions of FTLDU and ALS cases.
Performing Laboratory
West Virginia University Hospital, Inc.
